Aura Biosciences, Inc. (AURA) Cash Flow Statement
Aura Biosciences, Inc. (AURA) generated -$103.0M of operating cash flow over the twelve months to 2026-06-30, spent $344000 on capital expenditure and had free cash flow of -$103.4M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AURAAura Biosciences, Inc.Follow AURA — free
—
Price chart with a free account
- Market cap
- 653.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -32.4 | -54.6 | -63.8 | -79.8 | -84.7 | -103.0 | |
| Capital expenditure | 2.1 | 1.1 | 0.7 | 1.3 | 0.4 | -0.3 | |
| Free cash flow | -34.5 | -55.7 | -64.6 | -81.1 | -85.2 | -103.4 | |
| Stock-based compensation | 2.3 | 6.4 | 8.8 | 11.7 | 14.3 | — |
USD millions · SEC XBRL
Aura Biosciences, Inc. — questions
- What is Aura Biosciences, Inc.'s operating cash flow?
- -$103.0M over the twelve months to 2026-06-30.
- How much does Aura Biosciences, Inc. spend on capital expenditure?
- $344000 over the twelve months to 2026-06-30.
- What is Aura Biosciences, Inc.'s free cash flow?
- -$103.4M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Aura Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.